What is ALS Phase 3 Study Dexpramipexole (KNS-760704)?
Category: Others
See also: Clinical Trial
NCT01281189 is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Dexpramipexole was previously known as KNS-760704. Other study IDs: EMPOWER, 223AS302, EUDRA CT NO:2010-022818-19.
Purpose | Patients | Evaluations | Perceived Effectiveness |
---|---|---|---|
Amyotrophic lateral sclerosis | 38 | 96 | |
Participate in clinical trial | 17 | 21 | |
Increase effect of another treatment | 2 | 14 | |
Arthritis pain in shoulder joints | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
Severity | Evaluations | Percentage |
---|---|---|
Severe | 4 | |
Moderate | 4 | |
Mild | 28 | |
None | 66 |
Commonly reported side effects and conditions associated with ALS Phase 3 Study Dexpramipexole (KNS-760704)
Side effect | Patients | Percentage |
---|---|---|
Nausea | 3 | |
Heartburn | 2 | |
Insomnia | 2 | |
Neutropenia (low neutrophils) | 2 | |
Oily facial skin | 2 | |
Burning sensation in eyes | 1 |
Why patients stopped taking ALS Phase 3 Study Dexpramipexole (KNS-760704)
Multiple reasons could be selected
Reason | Patients | Percentage |
---|---|---|
Course of treatment ended | 12 | |
Other | 10 | |
Did not seem to work | 4 | |
Side effects too severe | 4 | |
Doctor's advice | 2 | |
Personal research | 1 |
Duration
Stopped using ALS Phase 3 Study Dexpramipexole (KNS-760704)
Duration | Patients | Percentage |
---|---|---|
Less than 1 month | 1 | |
1 - 6 months | 1 | |
6 months - 1 year | 2 | |
1 - 2 years | 19 | |
2 - 5 years | 1 |
Last updated: